$Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma$

Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma

Abstract Background Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfavorable risk factors. Herein, we evaluated the outc...

Full description

Bibliographic Details
Main Authors:	Chen Zhang, Jili Deng, Yan Xie, Lan Mi, Weiping Liu, Xiaopei Wang, Linjun Zhao, Yuqin Song, Jun Zhu
Format:	Article
Language:	English
Published:	Wiley 2023-05-01
Series:	Cancer Medicine
Subjects:	refractory or relapsed classical Hodgkin lymphoma single autologous stem cell transplantation tandem autologous stem cell transplantation unfavorable risk
Online Access:	https://doi.org/10.1002/cam4.5765

Similar Items

Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma
by: Sonja Genadieva Stavrik, et al.
Published: (2021-10-01)

Treatment of Hodgkin Lymphoma Relapsed after Autologous Stem Cell Transplantation
by: Eva Domingo-Domènech, et al.
Published: (2020-05-01)

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?
by: Radhika Takiar, et al.
Published: (2022-07-01)

Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study
by: Rosaria De Filippi, et al.
Published: (2022-11-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA
by: G. R. Khachatryan, et al.
Published: (2016-04-01)

Autologous Transplantation May Still Effectively Treat Relapsed Diffuse Large B-Cell Lymphoma in Selected Patients
by: Reka Rahel Bicsko, et al.
Published: (2023-06-01)

The Efficacy and Safety of Busulfan-Etoposide-Melphalan Regimen in Autologous Stem Cell Transplantation in Relapsed/ Refractory Hodgkin and Non-Hodgkin Lymphoma Patients: “A Single-Center Experience”
by: Ali Eser, et al.
Published: (2021-05-01)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma
by: Peiling Zhang, et al.
Published: (2022-10-01)

Combined immunochemotherapy in patients with refractory/relapsed classical Hodgkin's lymphoma as a 2<sup>nd</sup> line treatment before autologous hematopoietic stem cell transplantation (preliminary results)
by: A. A. Mamedova, et al.
Published: (2022-07-01)

The role of transplantation in Hodgkin lymphoma
by: Michael Maranzano, et al.
Published: (2023-01-01)

Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Lymphoma: Recent Advances and Outcomes
by: Taha Al-Juhaishi, et al.
Published: (2022-01-01)

Autologous Stem Cell Transplantation in Hodgkin Lymphoma—Latest Advances in the Era of Novel Therapies
by: Yazeed Samara, et al.
Published: (2022-03-01)

Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era
by: Huixing Zhou, et al.
Published: (2023-04-01)

Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis
by: Sulaiman Mohammed Alnasser, et al.
Published: (2023-12-01)

Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma in 38 Cases
by: HUANG Zhenghua, et al.
Published: (2022-09-01)

Outcomes of Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma Patients at a Tertiary Referral Centre
by: Ajay Prakash, et al.
Published: (2023-04-01)

Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
by: Parva Bhatt, et al.
Published: (2023-02-01)

Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
by: Lakshmi Yarlagadda, et al.
Published: (2021-08-01)

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
by: Birgit Burkhardt, et al.
Published: (2021-04-01)

Evaluating the Efficacy of Modified BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Regimen as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Lymphoma: An Experience from Two Centers of a Developing Country
by: Mani Ramzi, et al.
Published: (2023-04-01)

Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant
by: Oren Pasvolsky, et al.
Published: (2023-12-01)

Epidemiology of early infections and predictors of mortality after autologous hematopoietic stem-cell transplantation among multiple myeloma, Hodgkin, and non-Hodgkin lymphoma: the first experience from Palestine
by: Riad Amer, et al.
Published: (2022-09-01)

The Impact of <sup>131</sup>I-Metaiodobenzylguanidine as a Conditioning Regimen of Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma
by: Hyun Jin Park, et al.
Published: (2023-12-01)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
by: Bilgin YM
Published: (2022-09-01)

Prognostic Factors and a New Prognostic Index Model for Children and Adolescents with Hodgkin's Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation: A Multicenter Study of the Turkish Pediatric Bone Marrow Transplantation Study
by: Vural Kesik, et al.
Published: (2016-11-01)

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
by: Alejandro Martín García-Sancho, et al.
Published: (2023-12-01)

Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis
by: Min Wei, et al.
Published: (2023-12-01)

Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients
by: Aina Vaivade, et al.
Published: (2023-07-01)

The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin's lymphoma. Foreign recommendations and russian experience
by: N. V. Zhukov, et al.
Published: (2014-09-01)

The optimal time for autologous hematopoietic progenitor cell transplantation during treatment of Hodgkin's lymphoma. Foreign recommendations and russian experience
by: N. V. Zhukov, et al.
Published: (2014-09-01)

Autologous Faecal Microbiota Transplantation to Improve Outcomes of Haematopoietic Stem Cell Transplantation: Results of a Single-Centre Feasibility Study
by: Anna Li, et al.
Published: (2023-12-01)

Autologous hematopoietic stem cell transplantation in remission consolidation of acute myeloid leukemia with initially unfavorable prognostic factors
by: G. D. Petrova, et al.
Published: (2016-03-01)

A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation
by: Wancheng Guo, et al.
Published: (2024-03-01)

Comparison of single and double autologous stem cell transplantation in multiple myeloma patients
by: Malkan Umit Yavuz, et al.
Published: (2021-01-01)

Autologous and Allogeneic Hematopoetic Stem Cell Transplantation for Solid Tumors in Iran
by: Mohammad Jahani, et al.
Published: (2011-01-01)

Autologous and Allogeneic Hematopoetic Stem Cell Transplantation for Solid Tumors in Iran
by: Ardeshir Ghavamzadeh, et al.
Published: (2011-03-01)

Hematopoietic Stem Cell Transplantation in Iran: 1991 through 2010
by: Ardeshir Ghavamzadeh, et al.
Published: (2010-10-01)

Hematopoietic Stem Cell Transplantation in Iran: 1991 through 2010
by: Ardeshir Ghavamzadeh, et al.
Published: (2010-12-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
by: Wanying Liu, et al.
Published: (2024-02-01)